| Bioactivity | 6-β-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione-15N2 is 15N labeled (HY-154741). |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 0 --> 6-β-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione-15N2 相关抗体: |
| Name | 6-β-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione-15N2 |
| Formula | C9H1015N2O6 |
| Molar Mass | 244.17 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |